American College of Cardiology publishes more information about using the Kardia Mobile for Covid-19 patients
As an additional piece of information regarding our previous news from March the 26th, the American College of Cardiology ACC has published further information a couple of days ago: They published guidance on the management of COVID 19 patients treated with drugs that are prone to prolong QT duration. This guidance was in the meanwhile also linked from the ESC website (in their COVID19 section)
Under "Protocol Modifications in the Setting of Limited Resources or Quarantines” it says: "To further reduce exposure or save PPE resources, QTc monitoring may be performed using surrogates for 12-lead ECG assessment, including QTc monitoring via inpatient telemetry, direct-to-consumer mobile devices (e.g., KardiaMobile 6-lead, KardiaMobile 1-lead and Apple Watch 1-lead), or prescription mobile cardiac outpatient telemetry devices (e.g., iRhythm, BioTel and Preventice)."
As a result, we expect increased demand for the Kardia Mobile 6L and Kardia Mobile, especially from hospitals and healthcare facilities, in the next few weeks.
